NCT03973970 (IQ) is a clinical trial in Tuberculosis, sponsored by Oxford Immunotec.

Who is sponsoring NCT03973970?

NCT03973970 is sponsored by Oxford Immunotec.

What condition does NCT03973970 study?

NCT03973970 studies Tuberculosis.

Is NCT03973970 still recruiting?

NCT03973970 is currently completed. Last updated 24 February 2021.

Last reviewed 2021-02-24 · How we verify

NCT03973970: IQ

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessing the Ability of the T-SPOT®.TB Test (IQ)

Completed Last updated 24 February 2021

What this trial tests

trial in Tuberculosis in 201 participants. Completed in 30 June 2020.

Timeline

23 September 2019

Primary endpoint
30 June 2020

30 June 2020

Quick facts

Lead sponsor	Oxford Immunotec
Status	Completed
Study type	OBSERVATIONAL
Enrollment	201
Start date	23 September 2019
Primary completion	30 June 2020
Estimated completion	30 June 2020
Sites	1 location across United States

Conditions studied

Tuberculosis — all drugs for Tuberculosis →

Sponsor

Oxford Immunotec

Who can join

18 and older, any sex, with Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response (NTBSLR) in identifying patients with active TB disease. The secondary exploratory objective is to demonstrate that active TB cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based IGRA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Tuberculosis

Currently open trials in the same condition.

NCT05917210 — Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda · NA · recruiting
NCT07170735 — Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level · recruiting
NCT07484490 — Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis · NA · recruiting
NCT06318416 — Precision Rifampin Trial for Personalized Dosing · Phase 1 · recruiting
NCT07170800 — A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets · Phase 2 · recruiting

Other Oxford Immunotec trials

Trials by the same sponsor.

NCT04141982 — Clinical Concordance Evaluation of T-SPOT®.TB Assay Performance (T-Cell SelectTM Study) · completed
NCT03929705 — Assessing the Ability of the T-SPOT®.TB Test · completed
NCT03201042 — Lyme Test Indication Combinations (LyTIC) Study · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03973970 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oxford Immunotec
Last refreshed: 24 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03973970.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing